The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety
Abstract
OBJECTIVE: Long‐term experience of growth hormone (GH) replacement therapy in a large population of hypopituitary adults with GH deficiency (GHD) is limited, and safety surveillance is clearly essential. KIMS, the Pharmacia & Upjohn International Metabolic Database, is a long‐term, open, outcomes research programme of hypopituitary adult patients with GHD who are treated in a conventional clinical setting. PATIENTS: The present analysis encompasses data from 1034 hypopituitary adult GHD patients treated with GH for a total of 818 patient years. RESULTS: Prior to GH therapy, the KIMS patient population exhibited an increased prevalence of obesity, diabetes mellitus (in females) and hyperlipidaemia, compared with normal populations described in published studies. Quality of life, assessed using a disease‐specific questionnaire (QoL‐AGHDA), was also reduced in KIMS patients. The maintenance dose of GH was significantly higher in patients who were receiving GH prior to enrolment into KIMS (non‐naive patients) compared with patients who commenced GH at the time of enrolment (naive patients). In addition, dose of GH correlated significantly with body weight in the former group of patients. Analysis of serum levels of IGF‐I indicated that overtreatment with GH was markedly more common in non‐naive than in naive patients. The frequency of adverse events in KIMS patients was no higher than that reported in patients receiving placebo in previous clinical trials. Recurrence of pituitary or CNS tumours was reported in six patients, a rate consistent with data from control series. Three deaths were reported, none of which was obviously associated with GH treatment. CONCLUSIONS: Our data, drawn from a large population of hypopituitary adults treated with GH for a total of more than 800 patient years, confirm previous reports that untreated GHD in hypopituitary adults is associated with a number of important clinical problems. In addition, the results suggest that there has been a shift in recent years from determination of GH dose on the basis of body weight to dose titration of individual patients, and indicate that the latter technique has important advantages. The data provide further evidence that GH replacement therapy is well‐tolerated in adults. However, it is possible that some adverse events may not become evident over the time scale covered by the present analysis, and continued surveillance therefore remains mandatory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., & Pollak, M. (1998) · Science · doi:10.1126/science.279.5350.563 · Cited by 1,996
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., & Pollak, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10384-1 · Cited by 1,823
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Self-citationSalomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
BENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS
Jørgensen, J. O. L., Thuesen, L., Ingemann-Hansen, T., Pedersen, S. A., Jørgensen, I., Skakkebaek, N. E., & Christiansen, J. S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92328-3 · Cited by 890
Treatment of adults with growth hormone (GH) deficiency with recombinant human GH.
Bengtsson, B. A., Edén, S., Lönn, L., Kvist, H., Stokland, A., Lindstedt, G., Bosaeus, I., Tölli, J., Sjöström, L., & Isaksson, O. G. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.2.8432773 · Cited by 778
Self-citationThe Prolactin/Growth Hormone Receptor Family
KELLY, P. A., DJIANE, J., POSTEL-VINAY, M.-C., & EDERY, M. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-3-235 · Cited by 727
Clinical Aspects of Growth Hormone Deficiency in Adults
BOER, H. D., BLOK, G.-J., & DER VEEN, E. A. V. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-63 · Cited by 723
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
The effect of hypopituitarism on life expectancy.
Bates, A. S., Van't Hoff, W., Jones, P. J., & Clayton, R. N. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772595 · Cited by 475
Cited by
Karavitaki, N., Cudlip, S., Adams, C. B. T., & Wass, J. A. H. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0002 · Cited by 514
Serum levels of insulin-like growth factor I and its binding proteins in health and disease
Juul, A. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00038-8 · Cited by 467
Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu, H., Bravata, D. M., Olkin, I., Nayak, S., Roberts, B., Garber, A. M., & Hoffman, A. R. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-2-200701160-00005 · Cited by 370
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321
Self-citationKeleştimur, F. (2003) · Pituitary · doi:10.1023/b:pitu.0000023425.20854.8e · Cited by 304
Metadata
- Authors
- Abs, R., Bengtsson, B., Hernberg‐Ståhl, E., Monson, J. P., Tauber, J., Wilton, P., & Wüster, C.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1999-06
- Volume
- 50
- Issue
- 6
- Pages
- 703-713
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2095562369
- Cited by
- 267
- References
- 29
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. https://app.cochat.ai/papers/10.1046/j.1365-2265.1999.00695.x
- The paper
- Abs, R., Bengtsson, B., Hernberg‐Ståhl, E., Monson, J. P., Tauber, J., Wilton, P., & Wüster, C. (1999). GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1999.00695.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.